Maslow,
I am getting my head around this one, as a supportive supplement (I use this expression a bit loosely), it has the potential to reduce cost of the primary chemotherapy agent, so long as its own cost base is less than the primary and it is also transportable across multiple other more expensive agents.
Cheers.
